Qrono is a specialty pharmaceutical company enabling better medications, stronger patient adherence, improved patient outcomes, and faster time-to-market using an innovative technology to create long-acting injectable (LAI) formulations. These long-acting drug formulations enable a single administration of active pharmaceutical ingredient to provide a therapeutic effect ranging from several days to many weeks or months. Qrono Inc. reformulates approved drugs and creates LAIs with improved clinical and economic benefits for patients and other healthcare stakeholders. Qrono collapses the time and cost to develop these formulations and at the same time reduces technical and regulatory risk. The firm's pipeline strategy focuses on drugs with known safety profiles in therapeutic areas with either high non-adherence or with drug delivery challenges. The firm also further focuses on off patent medications to take advantage of the accelerated 505(j) and 505(b)(2) FDA regulatory pathways. Qrono is applying its proprietary predictive modeling technology, called QronoMetrics™, to develop these long-acting drug formulations significantly faster than in standard practice.
